{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:32:02Z","timestamp":1766050322060,"version":"build-2065373602"},"reference-count":96,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.neurol.2023.03.015","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:52:27Z","timestamp":1681314747000},"page":"405-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents"],"prefix":"10.1016","volume":"179","author":[{"given":"F.","family":"Bompaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Birzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Bihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Desestret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fargeot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Nichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Picca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tafani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Psimaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/eurpub\/ckn022","article-title":"Patient survival for all cancers combined as indicator of cancer control in Europe","volume":"18","author":"Verdecchia","year":"2008","journal-title":"Eur J Public Health"},{"issue":"9701","key":"10.1016\/j.neurol.2023.03.015_bib0010","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0140-6736(09)61299-X","article-title":"CNS complications of radiotherapy and chemotherapy","volume":"374","author":"Soussain","year":"2009","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10.1016\/j.neurol.2023.03.015_bib0015","first-page":"4217","article-title":"New insights in radiation-induced leukoencephalopathy: a prospective cross-sectional study","volume":"26","author":"Bompaire","year":"2018","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.015_bib0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1212\/WNL.0000000000000617","article-title":"APOE polymorphisms and cognitive functions in patients with brain tumors","volume":"83","author":"Correa","year":"2014","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.015_bib0025","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","article-title":"Delayed neurotoxicity in primary central nervous system lymphoma","volume":"62","author":"Omuro","year":"2005","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1212\/01.WNL.0000106941.51340.A2","article-title":"Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study","volume":"62","author":"Lai","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2023.03.015_bib0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fnins.2014.00145","article-title":"Oligodendrogenesis in the normal and pathological central nervous system","volume":"8","author":"El Waly","year":"2014","journal-title":"Front Neurosci"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.015_bib0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1667\/0033-7587(2000)153[0357:TROTCN]2.0.CO;2","article-title":"The radioresponse of the central nervous system: a dynamic process","volume":"153","author":"Tofilon","year":"2000","journal-title":"Radiat Res"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13014-023-02215-6","article-title":"Effects of whole-brain radiation therapy on the blood-brain barrier in immunocompetent and immunocompromised mouse models","volume":"18","author":"Blethen","year":"2023","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0050","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.1998.16.7.2522","article-title":"Methylphenidate therapy improves cognition, mood, and function of brain tumor patients","volume":"16","author":"Meyers","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.015_bib0055","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2005.03.3001","article-title":"Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life","volume":"24","author":"Shaw","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0060","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S1470-2045(15)00380-0","article-title":"Neurocognitive functioning and genetic variation in patients with primary brain tumours","volume":"17","author":"Wefel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0065","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1038\/s41598-021-89216-1","article-title":"Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors","volume":"11","author":"Terziev","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0070","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/fcp.12119","article-title":"Irbesartan, an angiotensin II receptor antagonist, with selective PPAR-gamma-modulating activity improves function and structure of chemotherapy-damaged ovaries in rats","volume":"29","author":"Abdel-Raheem","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1667\/RR13202.1","article-title":"The peroxisomal proliferator-activated receptor (PPAR) \u03b1 agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment","volume":"181","author":"Greene-Schloesser","year":"2014","journal-title":"Radiat Res"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.lungcan.2015.11.005","article-title":"A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model","volume":"90","author":"Mangoni","year":"2015","journal-title":"Lung Cancer Amst Neth"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12640-016-9679-4","article-title":"prevents radiation-induced neuroinflammation and preserves hippocampal neurogenesis in rats by inhibiting activation of NF-\u03baB and AP-1","volume":"31","author":"Zhang","year":"2017","journal-title":"Neurotox Res"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0090","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ijrobp.2009.06.059","article-title":"The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation","volume":"75","author":"Ramanan","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijrobp.2006.09.036","article-title":"Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment","volume":"67","author":"Zhao","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00432-018-2791-5","article-title":"Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial","volume":"145","author":"Cramer","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/08037050600771583","article-title":"Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE)\u00a0\u2013\u00a0a review","volume":"15","author":"Zanchetti","year":"2006","journal-title":"Blood Press"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0360-3016(97)00580-4","article-title":"Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma","volume":"40","author":"Lee","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00401-005-0023-y","article-title":"Cancer therapy-associated CNS neuropathology: an update and review of the literature","volume":"111","author":"Perry","year":"2006","journal-title":"Acta Neuropathol (Berl)"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0360-3016(99)00554-4","article-title":"Enhanced in vitro radiosensitivity of skin fibroblasts in two patients developing brain necrosis following AVM radiosurgery: a new risk factor with potential for a predictive assay","volume":"47","author":"Malone","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0125","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0360-3016(99)00513-1","article-title":"Development of a model to predict permanent symptomatic postradiosurgery injury for arteriovenous malformation patients. Arteriovenous Malformation Radiosurgery Study Group","volume":"46","author":"Flickinger","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0130","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.coc.0000128721.94095.e4","article-title":"Long-term survival after gamma knife radiosurgery for primary and metastatic brain tumors","volume":"27","author":"Jagannathan","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijrobp.2005.12.002","article-title":"Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy","volume":"65","author":"Ruben","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1148\/radiology.217.2.r00nv36377","article-title":"Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment","volume":"217","author":"Kumar","year":"2000","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-005-9018-8","article-title":"Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies","volume":"77","author":"Le Jeune","year":"2006","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.rcl.2004.09.009","article-title":"PET imaging for differentiating recurrent brain tumor from radiation necrosis","volume":"43","author":"Hustinx","year":"2005","journal-title":"Radiol Clin North Am"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.crad.2006.09.012","article-title":"The clinical value of proton magnetic resonance spectroscopy in adult brain tumours","volume":"62","author":"Sibtain","year":"2007","journal-title":"Clin Radiol"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0160","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/CCO.0000000000000793","article-title":"Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis","volume":"33","author":"Nichelli","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.015_bib0165","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<2005::AID-CNCR19>3.0.CO;2-0","article-title":"Hyperbaric oxygen therapy for radiation-induced brain injury in children","volume":"80","author":"Chuba","year":"1997","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0170","first-page":"4","article-title":"A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: an evidence based approach","volume":"29","author":"Feldmeier","year":"2002","journal-title":"Undersea Hyperb Med J Undersea Hyperb Med Soc Inc"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0175","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/0360-3016(90)90319-F","article-title":"The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs","volume":"18","author":"Hornsey","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.015_bib0180","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1212\/WNL.44.11.2020","article-title":"Treatment of radiation-induced nervous system injury with heparin and warfarin","volume":"44","author":"Glantz","year":"1994","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0185","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00415-010-5747-5","article-title":"Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis","volume":"258","author":"Benoit","year":"2011","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0190","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0195","first-page":"CD011492","article-title":"Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery","volume":"7","author":"Chung","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0200","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2018.04.068","article-title":"Bevacizumab monotherapy reduces radiation-induced brain necrosis in nasopharyngeal carcinoma patients: a randomized controlled trial","volume":"101","author":"Xu","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0205","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1212\/WNL.0000000000002345","article-title":"Bevacizumab in late-onset radiation-induced myelopathy","volume":"86","author":"Psimaras","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0210","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1097\/MPH.0000000000001714","article-title":"Dextromethorphan administration on Day 0 and Day 7 for secondary prevention of methotrexate-induced neurotoxicity in childhood acute lymphoblastic leukemia: a retrospective case series","volume":"43","author":"Fustino","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0215","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00415-022-11450-y","article-title":"Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study","volume":"270","author":"Balcerac","year":"2023","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.015_bib0220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jcpt.12160","article-title":"Regorafenib-induced hyperammonemic encephalopathy","volume":"39","author":"Kuo","year":"2014","journal-title":"J Clin Pharm Ther"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.015_bib0225","first-page":"2813","article-title":"Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib","volume":"23","author":"Peng","year":"2015","journal-title":"Support Care Cancer"},{"issue":"10094","key":"10.1016\/j.neurol.2023.03.015_bib0230","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.015_bib0235","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/0284186X.2020.1723163","article-title":"Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity","volume":"59","author":"Gendreau","year":"2020","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0240","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/jnnp-2020-323124","article-title":"Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies","volume":"91","author":"Fargeot","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0245","article-title":"Posterior reversible encephalopathy syndrome in patients with cancer","volume":"20","author":"Singer","year":"2015","journal-title":"The Oncologist [Internet]"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0250","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0000000000000578","article-title":"Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment","volume":"31","author":"Gibson","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0255","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0260","doi-asserted-by":"crossref","first-page":"e001034","DOI":"10.1136\/jitc-2020-001034","article-title":"Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients","volume":"8","author":"Cuzzubbo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0265","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1212\/NXI.0000000000000967","article-title":"Longitudinally extensive myelitis associated with immune checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"12","key":"10.1016\/j.neurol.2023.03.015_bib0270","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.neurol.2023.03.015_bib0275","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0280","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain J Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0285","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.015_bib0290","doi-asserted-by":"crossref","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.neurol.2023.03.015_bib0295","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.015_bib0300","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology [Internet]"},{"key":"10.1016\/j.neurol.2023.03.015_bib0305","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0310","article-title":"Chemotherapy-induced peripheral neuropathy: highlighting unmet needs","volume":"89","author":"Park","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry [Internet]"},{"key":"10.1016\/j.neurol.2023.03.015_bib0315","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CMAR.S44261","article-title":"Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature","volume":"6","author":"Argyriou","year":"2014","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0320","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1634\/theoncologist.2019-0255","article-title":"Guillain-Barr\u00e9 syndrome during platinum-based chemotherapy: a case series and review of the literature","volume":"25","author":"Pappa","year":"2020","journal-title":"The Oncologist"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0325","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10072-019-04199-2","article-title":"Axonal form of Guillain-Barr\u00e9 syndrome in a patient receiving oxaliplatin-based chemotherapy","volume":"41","author":"Tyberghein","year":"2020","journal-title":"Neurol Sci"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0330","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MPH.0b013e31816624a4","article-title":"Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia","volume":"30","author":"Nishikawa","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0335","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1468-1331.2007.01842.x","article-title":"Vincristine-induced acute neurotoxicity versus Guillain-Barr\u00e9 syndrome: a diagnostic dilemma","volume":"14","author":"Gonz\u00e1lez P\u00e9rez","year":"2007","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0340","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0345","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0350","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00415-020-10213-x","article-title":"Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature","volume":"268","author":"Okada","year":"2021","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0355","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0360","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neurol.2023.03.015_bib0365","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejca.2022.08.009","article-title":"Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study","volume":"175","author":"M\u00fcller-Jensen","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.neurol.2023.03.015_bib0370","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0375","doi-asserted-by":"crossref","first-page":"e200058","DOI":"10.1212\/NXI.0000000000200058","article-title":"Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors","volume":"10","author":"Farina","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.neurol.2023.03.015_bib0380","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0385","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1212\/NXI.0000000000001073","article-title":"Anti-interleukin-6 and Janus Kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors","volume":"8","author":"Picca","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"3","key":"10.1016\/j.neurol.2023.03.015_bib0390","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10072-021-05561-z","article-title":"Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience","volume":"43","author":"Diamanti","year":"2022","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2023.03.015_bib0395","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.neurol.2021.02.343","article-title":"Impact des immunoth\u00e9rapies anticanc\u00e9reuses par inhibiteurs de checkpoint sur l\u2019\u00e9volution et la prise en charge de la scl\u00e9rose en plaques","volume":"177","author":"Noroy","year":"2021","journal-title":"Rev Neurol (Paris)"},{"issue":"36","key":"10.1016\/j.neurol.2023.03.015_bib0400","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.neurol.2023.03.015_bib0405","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0410","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"10.1016\/j.neurol.2023.03.015_bib0415","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2021004889","article-title":"Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma","volume":"5","author":"Jung","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.neurol.2023.03.015_bib0420","doi-asserted-by":"crossref","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.neurol.2023.03.015_bib0425","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.015_bib0430","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.neurol.2023.03.015_bib0435","article-title":"Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project","volume":"27","author":"Foster","year":"2022","journal-title":"Mol Ther Oncolytics [Internet]"},{"issue":"2S","key":"10.1016\/j.neurol.2023.03.015_bib0440","article-title":"[Management of neurotoxicity following CAR-T cell therapy: recommendations of the SFGM-TC]","volume":"110","author":"Picard","year":"2023","journal-title":"Bull Cancer (Paris) [Internet]"},{"issue":"20","key":"10.1016\/j.neurol.2023.03.015_bib0445","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.neurol.2023.03.015_bib0450","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.neurol.2023.03.015_bib0455","first-page":"103331","article-title":"A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma","volume":"70","author":"Beauvais","year":"2022","journal-title":"Curr Res Transl Med"},{"issue":"5","key":"10.1016\/j.neurol.2023.03.015_bib0460","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.neurol.2023.03.015_bib0465","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.neurol.2023.03.015_bib0470","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/annonc\/mdp382","article-title":"Cetuximab-induced aseptic meningitis","volume":"20","author":"Feinstein","year":"2009","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.neurol.2023.03.015_bib0475","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.neurol.2023.03.015_bib0480","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1111\/bcp.15513","article-title":"Peripheral neuropathies after BRAF and\/or MEK inhibitor treatment: a pharmacovigilance study","volume":"88","author":"Picca","year":"2022","journal-title":"Br J Clin Pharmacol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378723008962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:47:09Z","timestamp":1758520029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378723008962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0035378723008962"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.015","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2023.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}